Nykode Therapeutics AS

Oslo Stock Exchange NYKD.OL

Nykode Therapeutics AS Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 44.59 M

Nykode Therapeutics AS Net Cash Used Provided By Financing Activities is USD 44.59 M for the year ending December 31, 2023, a 12,285.83% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Nykode Therapeutics AS Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 360.00 K, a -98.24% change year over year.
  • Nykode Therapeutics AS Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 20.44 M, a 7,148.62% change year over year.
  • Nykode Therapeutics AS Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -290.00 K, a -100.13% change year over year.
  • Nykode Therapeutics AS Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 227.08 M.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
SV Wall Street
Oslo Stock Exchange: NYKD.OL

Nykode Therapeutics AS

CEO Mr. Michael Thyring Engsig
IPO Date Oct. 7, 2020
Location Norway
Headquarters Oslo Research Park
Employees 179
Sector Healthcare
Industries
Vaccines Biotechnology
Description

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

StockViz Staff

February 7, 2025

Any question? Send us an email